Home HLA and Immune Genetics HLA Matching Test: Kidney, Bone Marrow, Organ Transplant, and Results

HLA Matching Test: Kidney, Bone Marrow, Organ Transplant, and Results

By
Vita Library
-
2
Understand HLA matching for kidney, bone marrow, stem-cell, and organ transplant, including 6/6, 8/8, 10/10, haploidentical, mismatch, antibody, and crossmatch results.

An HLA matching test compares inherited human leukocyte antigen markers between a transplant recipient and a potential donor. The meaning of a “good match” depends on the transplant. In kidney transplantation, closer matching can reduce immune recognition and may improve long-term graft survival, but antibody compatibility, donor quality, waiting time, and medical urgency also matter. In bone marrow or hematopoietic stem-cell transplantation, high-resolution matching at specific HLA genes is often a major donor-selection factor because mismatches can increase graft-versus-host disease, graft failure, and mortality. Heart, lung, liver, pancreas, and other organs use HLA information differently. Results may appear as 0/6, 8/8, 10/10, haploidentical, matched related, or mismatched unrelated, and these labels are not interchangeable. Matching does not predict success by itself. The transplant team combines HLA typing with antibody testing, crossmatch, age, organ or cell source, disease urgency, infections, donor health, and treatment strategy.

  • HLA matching compares donor and recipient immune markers; it is not the same as a crossmatch.
  • A 10/10 stem-cell match and a 0/6 kidney mismatch use different genes, resolution, and clinical rules.
  • A mismatch is not automatically unsafe; modern protocols permit many partially matched transplants.
  • Donor-specific HLA antibodies can make an otherwise acceptable match high risk.
  • The best donor is selected from the whole clinical picture, not the lowest mismatch count alone.

Table of Contents

What HLA Matching Means

HLA molecules are proteins on cell surfaces that display small protein fragments to immune cells. They are encoded by genes in the major histocompatibility complex on chromosome 6. HLA genes are among the most variable genes in humans, so unrelated people rarely have identical combinations.

Each person inherits one HLA haplotype from each biological parent. Siblings therefore have approximately a 25% chance of inheriting the same two haplotypes, a 50% chance of sharing one, and a 25% chance of sharing neither. These are probabilities for each sibling pair, not guarantees within a family.

The main classical HLA loci are:

  • Class I: HLA-A, HLA-B, and HLA-C
  • Class II: HLA-DRB1, HLA-DQB1, and HLA-DPB1, with additional linked genes in some evaluations

A match means donor and recipient have the same HLA antigen or allele at a tested locus. A mismatch means the donor carries an HLA form the recipient does not share. The immune system may recognize that difference as foreign.

Matching works in both directions, but the dominant risk differs by transplant. In a solid-organ transplant, the recipient’s immune system can reject donor tissue. In an allogeneic stem-cell transplant, donor immune cells can attack recipient tissues, causing graft-versus-host disease, while the recipient can also reject the donor cells.

HLA matching is not the same as blood-group matching. ABO type is determined by a different system. It is also not the same as the transplant crossmatch, which tests whether recipient antibodies react with donor cells or predicts that reaction virtually.

A perfect HLA match does not eliminate rejection, graft-versus-host disease, infection, relapse, or other complications. Thousands of non-HLA genetic differences and many clinical factors still separate donor and recipient.

How HLA Matching Is Tested and Reported

Both donor and recipient undergo HLA typing, usually from blood or a cheek-swab sample. DNA-based methods identify HLA variants. The laboratory then compares results locus by locus.

The level of detail is called resolution:

  • Low resolution identifies broad antigen groups, often represented by the first field of an allele name.
  • Intermediate resolution narrows the possible alleles but may leave ambiguity.
  • High resolution usually identifies the allele at the protein-coding level, commonly the first two fields, such as HLA-A*02:01.

A complete HLA typing test can produce many allele names. The matching report simplifies the comparison into the loci most relevant to that transplant program.

Match fractions use the number of matched alleles over the number evaluated. Because each person has two alleles at most loci:

  • 6/6 may refer to HLA-A, HLA-B, and HLA-DR, counted twice each.
  • 8/8 commonly refers to high-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1.
  • 10/10 adds HLA-DQB1.
  • 12/12 may add HLA-DPB1, though usage varies.

Always ask which loci and resolution are included. A “10/10” label from one program may not include the same secondary factors as another.

Related-donor reports may use “HLA-identical sibling,” “matched related donor,” or “haploidentical donor.” Haploidentical usually means the donor shares one inherited HLA haplotype with the recipient, as often occurs with a parent, child, or half-matched sibling.

Typing may initially be performed from a registry sample and then repeated on a fresh specimen for confirmation. This reduces sample mix-up and ensures that the final donor-selection decision uses verified high-resolution data.

Matching is only one stage. The recipient also undergoes HLA antibody testing. If an antibody targets a mismatched donor HLA, it is donor-specific and may outweigh the simple numerical match count.

HLA Matching for Kidney Transplant

Kidney allocation historically emphasized HLA-A, HLA-B, and HLA-DR. A 0/6 mismatch means the donor and recipient match at all two copies of those three loci; a 6/6 mismatch means none of the counted antigens match. Depending on the reporting convention, the same concept may be stated as 6/6 matched rather than 0 mismatches.

Closer matching can reduce the likelihood of T-cell and antibody responses, lower the risk of developing donor-specific antibodies, and improve graft longevity. HLA-DR and HLA-DQ compatibility are particularly important for immune risk. However, the benefit of waiting for a closer match must be balanced against time on dialysis, organ quality, age, sensitization, and geographic availability.

A living donor with several HLA mismatches may still be an excellent choice. Living-donor kidneys often have short cold-ischemia time, planned surgery, and favorable organ quality. For many patients, these benefits outweigh the theoretical advantage of waiting years for a better deceased-donor HLA match.

The antibody profile can radically change interpretation. A four-antigen mismatch with no donor-specific antibody and a negative crossmatch may be safer than a one-antigen mismatch that includes a strong antibody target. The HLA antibody result therefore belongs beside the mismatch count.

Kidney paired donation can improve compatibility when a willing living donor is blood-group or HLA-antibody incompatible. Donor-recipient pairs exchange donors within a chain so each recipient receives a more suitable kidney.

Pediatric recipients may gain particular value from good matching because they are likely to need the graft for many decades and may require future transplants. Avoiding sensitization is also important because antibodies formed against the first graft can make a later transplant difficult.

Modern molecular mismatch methods assess smaller structural differences rather than counting whole antigens. They may help estimate the probability of de novo HLA-DQ or other antibodies and guide immunosuppression research. These tools are promising but do not yet replace established allocation, antibody, and crossmatch practices.

HLA Matching for Bone Marrow and Stem-Cell Transplant

HLA matching has a different level of urgency in allogeneic hematopoietic cell transplantation. Donor stem cells rebuild the recipient’s immune system. Donor T cells can recognize recipient HLA and tissues as foreign, while recipient immunity can resist engraftment.

For an unrelated adult donor, programs commonly seek high-resolution matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1, reported as 8/8. Many also include HLA-DQB1, producing a 10/10 description. HLA-DPB1 is usually evaluated separately because a DPB1 match is less common and some mismatches are considered permissive.

A matched sibling donor has historically been preferred for many diseases, but donor age, health, cytomegalovirus status, sex and pregnancy history, cell source, and disease-specific factors can alter the hierarchy. A young matched unrelated donor may be favored over an older related donor in some settings.

When no fully matched donor is available, alternatives include:

  • A 7/8 mismatched unrelated donor
  • A haploidentical related donor
  • Umbilical cord blood
  • A mismatched unrelated donor under a post-transplant cyclophosphamide protocol

Modern graft-versus-host disease prevention has expanded safe access to partially matched donors. Haploidentical transplantation can provide a rapid family donor for many patients. Cord blood tolerates more HLA disparity than adult donor grafts but has different cell-dose and engraftment considerations.

Not every mismatch has equal effect. The locus, amino-acid position, HLA expression, direction of mismatch, and transplant platform matter. HLA-C mismatches may carry different risk from HLA-A or HLA-B mismatches. HLA-DPB1 mismatches can be classified as permissive or nonpermissive using T-cell epitope models.

Recipient donor-specific antibodies are especially important in haploidentical and other mismatched transplants. Strong DSA can increase graft failure risk. The team may choose another donor or use a desensitization plan before conditioning.

The best donor must also be available quickly enough. For aggressive leukemia, a modestly mismatched donor who can proceed promptly may be better than waiting for a theoretical ideal donor while the disease progresses.

Matching for Heart, Lung, Liver, and Other Organs

HLA information is collected for most solid-organ transplants, but its weight in allocation differs because organs tolerate immune mismatch differently and have different time pressures.

Heart transplant

Heart candidates often cannot wait for close HLA matching because organ availability and medical urgency dominate. HLA antibody and virtual crossmatch assessment are crucial for sensitized recipients. Size, blood group, donor age, ischemic time, and organ function may be more immediate determinants than allele matching.

Lung transplant

Lung recipients face substantial rejection risk, and donor-specific antibodies can contribute to antibody-mediated rejection and chronic lung allograft dysfunction. Allocation usually prioritizes urgency, size, blood group, and geography rather than waiting for a close HLA match, but antibody avoidance remains important.

Liver transplant

The liver is relatively tolerant of HLA mismatch compared with kidney, heart, or lung. HLA matching is not usually a primary allocation requirement. Some donor-specific antibodies can still matter, especially in selected high-risk settings, retransplantation, or combined-organ procedures.

Pancreas and islet transplant

HLA matching may influence long-term immune risk, but donor quality, surgical factors, kidney status, and antibody compatibility are also central. Simultaneous kidney-pancreas transplantation requires an integrated assessment.

Cornea and other tissues

Routine corneal transplantation often succeeds without HLA matching because the eye has relative immune privilege. High-risk repeat grafts or inflamed eyes may be handled differently in some systems. Other tissues and cellular therapies have procedure-specific compatibility rules.

A patient should not compare match scores across organ types. A kidney mismatch count, stem-cell 10/10 result, and heart virtual crossmatch answer different questions.

Understanding Match Results

Full or complete match

A full match means donor and recipient match at all loci included in that report. It does not mean their entire genomes or all HLA genes are identical. A 10/10 match can still have HLA-DPB1 differences, nonclassical HLA differences, minor histocompatibility antigens, and non-HLA immune targets.

Partial match

A partial match means one or more counted alleles differ. The report should identify the exact locus. A one-locus mismatch may have a different effect depending on whether it is HLA-A, B, C, DRB1, DQB1, or DPB1 and which transplant platform is planned.

Haploidentical result

A haploidentical donor shares one parental HLA haplotype. This is expected for biological parents and children and occurs in about half of siblings. It is not a “50% match” in a simple genome-wide sense. The shared and unshared HLA alleles are evaluated in detail, along with DSA and donor characteristics.

Mismatch count of zero

In kidney terminology, “zero mismatch” often means no mismatch at selected loci, historically HLA-A, B, and DR. It may not include HLA-C, DQ, DP, allele-level differences, or eplets. Ask for the definition used by the allocation system.

Permissive mismatch

A permissive mismatch is a difference predicted or observed to carry less risk under a specific model. HLA-DPB1 permissiveness is commonly used in unrelated stem-cell donor selection. The term does not mean no risk, and it should not be generalized to another locus or transplant type.

Unexpected or ambiguous result

If the result conflicts with reported biological relationships, the laboratory first considers sample identity, low-resolution ambiguity, recent transfusion, or a stem-cell transplant that changed blood-derived DNA. Confirmatory testing from another tissue may be needed. HLA testing can sometimes reveal unexpected parentage or donor chimerism, so pretest counseling should address that possibility.

Eplets, Expression, and Other Advanced Factors

Traditional matching counts whole antigens or alleles. Advanced models examine why some mismatches stimulate stronger immune responses than others.

An eplet is a small patch of amino acids on the HLA surface that an antibody may recognize. Molecular mismatch algorithms count donor eplets absent in the recipient. A higher load, especially at HLA-DQ in kidney transplantation, has been associated with more de novo donor-specific antibody in groups of patients.

Eplet counts are not yet universal clinical cutoffs. Different software versions, HLA typing resolution, and definitions can change the result. Some eplets are well verified by antibody data; others are theoretical.

HLA expression also matters. Certain HLA-C or HLA-DP alleles are displayed at higher levels on cells, potentially changing mismatch effects. In stem-cell transplantation, HLA-C expression, HLA-B leader sequence, and HLA-DPB1 T-cell epitope grouping can refine donor selection.

Direction matters in hematopoietic transplantation. A host-versus-graft mismatch can affect engraftment, while graft-versus-host recognition can affect GVHD and antileukemia activity. Bidirectional mismatches may carry both effects.

Non-HLA donor factors may override small HLA differences. In stem-cell donation, younger age often predicts better outcomes. Cytomegalovirus matching, donor-specific antibodies, sex and pregnancy history, ABO type, availability, and cell source may enter the final ranking.

In solid-organ transplantation, kidney donor age, function, ischemic time, organ anatomy, infection risk, recipient urgency, and waiting time are critical. A sophisticated molecular match does not make a poor-quality organ ideal, and a less favorable molecular score does not automatically make a healthy living-donor kidney unacceptable.

Advanced matching is most useful as an additional risk layer. It can guide research, counseling, and perhaps immunosuppression intensity, but the proven foundations remain accurate HLA typing, antibody specificity, crossmatch, and transplant-specific clinical judgment.

Next Steps After HLA Matching

Ask for the actual donor and recipient HLA typing and the definition behind the match score. A useful discussion should cover:

  1. Which HLA loci were compared?
  2. Was typing low, intermediate, or high resolution?
  3. Is the result expressed as matches or mismatches?
  4. Does the recipient have antibodies against any donor HLA?
  5. What do the virtual and physical crossmatches show?
  6. Are HLA-DPB1 permissiveness, eplets, or HLA expression relevant?
  7. Which non-HLA donor factors affect the choice?
  8. Would waiting for another donor improve or worsen overall risk?

For kidney transplant, compare the proposed donor’s medical quality, antibody compatibility, expected waiting time, and living-versus-deceased donor benefits. Ask about paired donation if a living donor is incompatible.

For stem-cell transplant, request the ranked donor-selection rationale. The team should explain HLA match, donor age, DSA, cytomegalovirus status, cell source, availability, and the planned GVHD-prevention platform. Do not assume that a related donor is always preferred or that a 10/10 donor is automatically better in every circumstance.

If testing was performed years ago, confirm whether higher-resolution typing is needed. HLA nomenclature and laboratory methods have evolved, and donor registries often obtain confirmatory samples before collection.

Tell the laboratory about a previous allogeneic stem-cell transplant or recent transfusion. Blood-derived DNA after stem-cell transplant may represent the donor rather than the recipient. A cheek swab, hair follicles, or another nonblood source may be required for the recipient’s original genotype.

Keep copies of the full reports. Match labels alone lose important detail. If care moves to another center, transfer donor typing, recipient typing, antibody history, and crossmatch records.

HLA matching reduces uncertainty; it does not eliminate it. A well-chosen donor is the one whose immunologic profile, medical quality, availability, and transplant strategy offer the best overall balance for that specific patient.

Match labels must always be tied to the loci and resolution used. A “6/6” kidney match may refer to broad HLA-A, HLA-B, and HLA-DR antigens, while an “8/8” stem-cell match commonly refers to allele-level HLA-A, HLA-B, HLA-C, and HLA-DRB1. A “10/10” adds another locus, often HLA-DQB1. Programs may count HLA-DPB1, HLA-DRB3/4/5, or other features separately. The same fraction can therefore describe different biological comparisons at different centers.

When several donors are available, HLA is one part of a ranked choice. For kidney transplantation, a healthy living donor with a manageable mismatch can offer more benefit than waiting years for a theoretically closer deceased donor. For hematopoietic transplantation, donor age, availability, cytomegalovirus status, sex and pregnancy history, stem-cell source, and urgency can distinguish otherwise similar HLA matches. Modern graft-versus-host disease prevention may make haploidentical relatives or mismatched unrelated donors realistic options when a fully matched donor is unavailable.

Structural or epitope matching can refine risk beyond simple antigen counts. Two alleles may differ in name but share many exposed amino-acid structures, while a single mismatch may contain an epitope strongly recognized by antibodies or T cells. These newer models are useful for selected decisions, especially retransplantation and pediatric allocation, but they require validated laboratory interpretation and should not be reduced to a consumer-style compatibility score.

A match report should also state whether the donor typing was confirmed on a second sample and whether the recipient has been recently transfused or transplanted. Urgent deceased-donor work may begin with rapid, lower-resolution data and be refined later. When a later result changes an allele assignment, the team reassesses antibody specificity and compatibility rather than assuming that the original allocation decision was careless; the tests answered different time-sensitive questions.

For patients, the most useful request is a plain-language summary that separates three issues: inherited HLA similarity, preformed recipient antibodies, and the final clinical donor assessment. A donor can be less closely matched yet antibody-compatible, or closely matched but unsafe because of a strong donor-specific antibody. These are related dimensions, not one score.

References

Disclaimer

This article provides general information and cannot rank donors for an individual transplant. HLA match results must be interpreted by the transplant team and histocompatibility laboratory with antibody, crossmatch, donor health, disease urgency, and transplant-protocol information. Do not accept or decline a donor based only on a match fraction.

RELATED ARTICLESMORE FROM AUTHOR